文献速递肿瘤 PET/CT

FAPI PET与FDG PET/CT在胃肠道肿瘤中的对比:综述

FAPI PET Versus FDG PET/CT in Gastrointestinal Cancers: An Overview.
PubMed 文献 · Semin Nucl Med · 2025-05-21

本文综述比较了放射性标记成纤维细胞激活蛋白抑制剂(FAPI)PET与[18F]FDG PET在胃肠道(GI)肿瘤中的临床应用,涵盖诊断、分期和治疗指导价值。GI肿瘤常伴促结缔组织增生反应且富含表达FAP的癌相关成纤维细胞,适合FAPI PET。鉴于[18F]FDG PET在部分组织学亚型中敏感性低及生理性背景摄取高,FAPI PET有望作为补充方法,可能提升诊断准确性和治疗指导。

要点

  • FAP在癌相关成纤维细胞中高表达,其过表达与多种癌症不良预后及治疗抵抗相关。
  • 胃肠道肿瘤常伴促结缔组织增生反应且FAP表达癌相关成纤维细胞密度高,尤其适合FAPI PET。
  • FAPI PET有望作为[18F]FDG PET的补充方法,可能提升诊断准确性和治疗指导。

核心结论

  • FAPI PET有望作为[18F]FDG PET的补充方法,可能提升胃肠道肿瘤的诊断准确性和治疗指导。

研究设计与样本

  • 本文为综述,比较FAPI PET与[18F]FDG PET在多种胃肠道肿瘤中的临床应用。

主要发现

  • 放射性标记FAPI用于PET成像在多种癌症中已显示出有前景的临床价值。
  • 胃肠道肿瘤常伴促结缔组织增生反应且富含表达FAP的癌相关成纤维细胞,尤其适合FAPI PET。
  • 综述汇总了FAPI PET在评估治疗反应和预测预后方面不断扩展的作用。

关键数值与推荐

  • [18F]FDG PET在胃肠道肿瘤中的局限性包括某些组织学亚型敏感性低和生理性背景摄取高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is a type II transmembrane serine protease that is highly expressed in cancer-associated fibroblasts (CAFs) but absent in quiescent fibroblasts. Its overexpression is associated with poor prognosis in various cancers and contributes to treatment resistance. In recent years, radiolabeled FAP inhibitors (FAPI) for PET imaging have shown promising clinical value across a range of cancers. Gastrointestinal (GI) malignancies, which often exhibit a desmoplastic reaction with a high density of FAP-expressing CAFs, are particularly well-suited for FAPI PET. Given the limitations of [18F]FDG PET in GI cancers, such as low sensitivity in certain histological subtypes and high physiological background uptake, FAPI PET is expected to serve as a complementary method, potentially enhancing both diagnostic accuracy and treatment guidance. This review provides a comprehensive comparison of the clinical applications of FAPI PET and [18F]FDG PET in various GI cancers, including their value in diagnosis, staging, and treatment guidance. Additionally, this review summarizes studies on the expanding role of FAPI PET, including its use in assessing treatment response and predicting prognosis, aiming to provide insights into its potential contribution to the improved management of GI malignancies.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lin Z, Rasinski P, Nilsson T, et al. FAPI PET Versus FDG PET/CT in Gastrointestinal Cancers: An Overview. Semin Nucl Med. 2025. PMID: 40399164. doi:10.1053/j.semnuclmed.2025.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。